Oregon Public Employees Retirement Fund Purchases 1,931 Shares of Insulet Corporation $PODD

Oregon Public Employees Retirement Fund lifted its position in shares of Insulet Corporation (NASDAQ:PODD) by 31.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,040 shares of the medical instruments supplier’s stock after purchasing an additional 1,931 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Insulet were worth $2,482,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PODD. True Wealth Design LLC lifted its stake in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Golden State Wealth Management LLC increased its position in shares of Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares in the last quarter. Kozak & Associates Inc. acquired a new stake in shares of Insulet in the 2nd quarter worth about $32,000. Trust Co. of Toledo NA OH bought a new position in Insulet in the 2nd quarter valued at about $35,000. Finally, Osterweis Capital Management Inc. bought a new stake in Insulet during the 2nd quarter worth approximately $51,000.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PODD shares. Wells Fargo & Company lifted their target price on Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Stifel Nicolaus assumed coverage on shares of Insulet in a report on Tuesday, October 21st. They set a “buy” rating and a $370.00 price objective on the stock. BTIG Research increased their target price on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a report on Friday, November 21st. Leerink Partners boosted their price target on shares of Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Barclays increased their price objective on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 5th. Twenty-one equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Insulet presently has an average rating of “Moderate Buy” and an average target price of $379.10.

Insulet Stock Performance

NASDAQ PODD opened at $278.55 on Tuesday. The company has a market capitalization of $19.60 billion, a PE ratio of 80.74, a price-to-earnings-growth ratio of 1.61 and a beta of 1.40. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. Insulet Corporation has a 52-week low of $230.05 and a 52-week high of $354.88. The company has a 50-day simple moving average of $306.15 and a 200 day simple moving average of $311.62.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The firm had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The company’s revenue was up 29.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.08 EPS. On average, research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.